RU2275354C2 - Способы получения кристаллов в-типа натеглинида - Google Patents
Способы получения кристаллов в-типа натеглинида Download PDFInfo
- Publication number
- RU2275354C2 RU2275354C2 RU2003111948/04A RU2003111948A RU2275354C2 RU 2275354 C2 RU2275354 C2 RU 2275354C2 RU 2003111948/04 A RU2003111948/04 A RU 2003111948/04A RU 2003111948 A RU2003111948 A RU 2003111948A RU 2275354 C2 RU2275354 C2 RU 2275354C2
- Authority
- RU
- Russia
- Prior art keywords
- crystals
- type
- nateglinide
- temperature
- nateglynide
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 229960000698 nateglinide Drugs 0.000 claims description 37
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 34
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 3
- -1 nateglinide hydrates Chemical class 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012453 solvate Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-324375 | 2000-10-24 | ||
| JP2000324375 | 2000-10-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003111948A RU2003111948A (ru) | 2004-09-20 |
| RU2275354C2 true RU2275354C2 (ru) | 2006-04-27 |
Family
ID=18801920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003111948/04A RU2275354C2 (ru) | 2000-10-24 | 2001-10-23 | Способы получения кристаллов в-типа натеглинида |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030229249A1 (OSRAM) |
| EP (1) | EP1334964B1 (OSRAM) |
| JP (1) | JP4225057B2 (OSRAM) |
| KR (1) | KR100810930B1 (OSRAM) |
| CN (1) | CN100422143C (OSRAM) |
| AT (1) | ATE370115T1 (OSRAM) |
| AU (1) | AU2001296001A1 (OSRAM) |
| BR (1) | BR0114846A (OSRAM) |
| CA (1) | CA2426745C (OSRAM) |
| CY (1) | CY1106839T1 (OSRAM) |
| DE (1) | DE60130014T2 (OSRAM) |
| DK (1) | DK1334964T3 (OSRAM) |
| ES (1) | ES2288997T3 (OSRAM) |
| MX (1) | MXPA03003575A (OSRAM) |
| PT (1) | PT1334964E (OSRAM) |
| RU (1) | RU2275354C2 (OSRAM) |
| TW (1) | TWI293290B (OSRAM) |
| WO (1) | WO2002034713A1 (OSRAM) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0109336A (pt) * | 2000-03-17 | 2003-06-24 | Ajinomoto C0 Inc | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico |
| RU2287520C2 (ru) * | 2000-10-18 | 2006-11-20 | Адзиномото Ко., Инк. | Способ получения ацилфенилаланинов |
| AU2001294265A1 (en) * | 2000-10-18 | 2002-04-29 | Ajinomoto Co., Inc. | Process for producing nateglinide crystal |
| DK1334720T3 (da) * | 2000-10-24 | 2009-01-19 | Ajinomoto Kk | Nateglinid-indeholdende fremstillinger |
| DE60138476D1 (de) * | 2000-10-24 | 2009-06-04 | Ajinomoto Kk | Nateglinid enthaltende hydrophile arzneimittelpräparate |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| EP1496048A4 (en) * | 2002-04-15 | 2006-08-02 | Ajinomoto Kk | NEW NATEGLINID CRYSTAL |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| JP2006511614A (ja) * | 2002-07-18 | 2006-04-06 | テバ ファーマシューティカル インダストリーズ リミティド | ナテグリニドの多形性形状 |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) * | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| EP1535900B1 (en) * | 2003-11-26 | 2006-12-27 | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. | Process for the preparation of nateglinide, preferably in b-form |
| KR20080086937A (ko) * | 2004-05-07 | 2008-09-26 | 테바 파마슈티컬 인더스트리즈 리미티드 | 나테글리나이드의 다형태 |
| US20070231393A1 (en) * | 2004-05-19 | 2007-10-04 | University Of South Carolina | System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles |
| US20080096970A1 (en) * | 2004-05-20 | 2008-04-24 | Sundaram Venkataraman | Stable Nateglinide Form B Compositions |
| US7425648B2 (en) | 2005-01-03 | 2008-09-16 | A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. | Process for the preparation of nateglinide, preferably in B-form |
| WO2006080524A1 (ja) * | 2005-01-31 | 2006-08-03 | Ajinomoto Co., Inc. | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
| WO2007135533A1 (en) * | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
| KR100837843B1 (ko) * | 2006-12-26 | 2008-06-13 | 씨제이제일제당 (주) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 |
| WO2011157986A1 (en) | 2010-06-14 | 2011-12-22 | Cipla Limited | A process for the preparation of nateglinide |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| WO2013167985A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| EP2847161A4 (en) * | 2012-05-08 | 2015-12-23 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING DIABETES |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| CN104583182A (zh) | 2012-05-23 | 2015-04-29 | 塞利克斯比奥私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
| SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| AU2013264894B2 (en) | 2012-05-23 | 2015-11-19 | Cellix Bio Private Limited | Compositions and methods for treatment of inflammatory bowel disease |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| WO2014037834A2 (en) | 2012-09-08 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| SG11201702554QA (en) | 2014-09-29 | 2017-04-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
| SG11201703369WA (en) | 2014-10-27 | 2017-05-30 | Cellix Bio Private Ltd | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| CN104402756B (zh) * | 2014-11-27 | 2016-08-31 | 天方药业有限公司 | 一种高纯度那格列奈的制备方法 |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CA2973178C (en) | 2015-01-06 | 2022-11-01 | Cellix Bio Private Limited | Bupivacaine derivatives and their use in the treatment of inflammation and pain |
| CN109369443A (zh) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种新的那格列奈h晶型的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0196222B1 (en) * | 1985-03-27 | 1992-01-29 | Ajinomoto Co., Inc. | Hypoglycemic agent |
| RU2007407C1 (ru) * | 1987-12-04 | 1994-02-15 | Такеда Кемикал Индастриз ЛТД | СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛОВ ГИДРОХЛОРИДА ГИДРАТА 7- β -[(Z)-2-(5-АМИНО - 1,2,4-ТИАДИАЗОЛ - 3-ИЛ)-2-МЕТОКСИИМИНОАЦЕТАМИДО] - 3 - [1-ИМИДАЗО-(1,2-B) ПИРИДАЗИН]МЕТИЛ - 3 - ЦЕФЕМ-4-КАРБОКСИЛАТА ИЛИ ЕГО СОЛЬВАТОВ |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE149483T1 (de) * | 1991-07-30 | 1997-03-15 | Ajinomoto Kk | Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung |
| WO1998022105A1 (en) * | 1996-11-15 | 1998-05-28 | Ajinomoto Co., Inc. | Tabletted preparation |
| US6844006B1 (en) * | 1999-07-09 | 2005-01-18 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
| ES2305977T3 (es) * | 1999-12-28 | 2008-11-01 | Ajinomoto Co., Inc. | Preparacion antidiabetica para administracion oral. |
| BR0109336A (pt) * | 2000-03-17 | 2003-06-24 | Ajinomoto C0 Inc | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico |
| AU2001294265A1 (en) * | 2000-10-18 | 2002-04-29 | Ajinomoto Co., Inc. | Process for producing nateglinide crystal |
| RU2287520C2 (ru) * | 2000-10-18 | 2006-11-20 | Адзиномото Ко., Инк. | Способ получения ацилфенилаланинов |
| DK1334720T3 (da) * | 2000-10-24 | 2009-01-19 | Ajinomoto Kk | Nateglinid-indeholdende fremstillinger |
| US7411089B2 (en) * | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
-
2001
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active Expired - Fee Related
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja not_active Ceased
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
-
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0196222B1 (en) * | 1985-03-27 | 1992-01-29 | Ajinomoto Co., Inc. | Hypoglycemic agent |
| RU2007407C1 (ru) * | 1987-12-04 | 1994-02-15 | Такеда Кемикал Индастриз ЛТД | СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛОВ ГИДРОХЛОРИДА ГИДРАТА 7- β -[(Z)-2-(5-АМИНО - 1,2,4-ТИАДИАЗОЛ - 3-ИЛ)-2-МЕТОКСИИМИНОАЦЕТАМИДО] - 3 - [1-ИМИДАЗО-(1,2-B) ПИРИДАЗИН]МЕТИЛ - 3 - ЦЕФЕМ-4-КАРБОКСИЛАТА ИЛИ ЕГО СОЛЬВАТОВ |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
Also Published As
| Publication number | Publication date |
|---|---|
| CY1106839T1 (el) | 2012-05-23 |
| DE60130014T2 (de) | 2008-05-08 |
| CN1483018A (zh) | 2004-03-17 |
| EP1334964B1 (en) | 2007-08-15 |
| MXPA03003575A (es) | 2003-07-14 |
| US7544834B2 (en) | 2009-06-09 |
| EP1334964A4 (en) | 2005-09-28 |
| CA2426745C (en) | 2009-09-15 |
| CN100422143C (zh) | 2008-10-01 |
| JPWO2002034713A1 (ja) | 2004-03-04 |
| WO2002034713A1 (en) | 2002-05-02 |
| TWI293290B (OSRAM) | 2008-02-11 |
| KR20030059212A (ko) | 2003-07-07 |
| US20070232829A1 (en) | 2007-10-04 |
| AU2001296001A1 (en) | 2002-05-06 |
| DE60130014D1 (de) | 2007-09-27 |
| KR100810930B1 (ko) | 2008-03-10 |
| CA2426745A1 (en) | 2003-04-23 |
| ATE370115T1 (de) | 2007-09-15 |
| DK1334964T3 (da) | 2007-09-24 |
| BR0114846A (pt) | 2004-02-25 |
| EP1334964A1 (en) | 2003-08-13 |
| PT1334964E (pt) | 2007-09-20 |
| ES2288997T3 (es) | 2008-02-01 |
| US20030229249A1 (en) | 2003-12-11 |
| JP4225057B2 (ja) | 2009-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2275354C2 (ru) | Способы получения кристаллов в-типа натеглинида | |
| US6022985A (en) | Process for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrate | |
| RU2273629C2 (ru) | Способы получения кристаллов натеглинида | |
| WO2008134936A1 (en) | Method for extracting threonine from threonine fermentation liquor | |
| AU738545B2 (en) | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent | |
| EP0450684B1 (en) | A process for the preparation of D-(-)-4-hydroxyphenylglycine and L-(+)-4-hydroxyphenylglycine, starting from D.L.-4-hydroxyphenylglycine | |
| JP2000517312A (ja) | イオヘキソールの製法 | |
| RU2764573C2 (ru) | Улучшенный синтез частиц ацетилсалицилата лизина ⋅ глицина | |
| JPS6213942B2 (OSRAM) | ||
| JP2971291B2 (ja) | 光学活性２−アミノ酪酸の製法 | |
| CN110283109B (zh) | 一种工业化制备消旋卡多曲的方法 | |
| JP5419570B2 (ja) | ２−アセチルアミノメチル−４−（４−フルオロベンジル）モルホリンの精製方法 | |
| US20080275252A1 (en) | Atipamezole Hydrochloride Crystallization Method | |
| JP3923798B2 (ja) | フマギリンの調製プロセス | |
| JPS62294637A (ja) | 粗イブプロフエンの精製方法 | |
| JP3831476B2 (ja) | キシロースの精製方法 | |
| SU1155604A1 (ru) | Способ очистки левоглюкозана | |
| JPS60184054A (ja) | 光学活性リジンの精製方法 | |
| JP2003146962A (ja) | Ｎ−アルコキシカルボニル−ｔｅｒｔ−ロイシンの回収方法 | |
| JPH1180099A (ja) | （１ｓ，２ｒ）−１−アミノ−２−インダノール−（ｒ，ｒ）−タートレート メタノール溶媒和物の調製方法 | |
| JPH05112488A (ja) | １０−ヒドロキシ−δ−２−デセン酸の製法 | |
| SU810673A1 (ru) | Способ получени оптических изо-MEPOB АММОНиЕВОй СОли -АцЕТил- -АМиНОфЕНилуКСуСНОй КиСлОТы | |
| SU1334651A1 (ru) | Способ выделени хлоргидрата D, L-трео-1-п-нитрофенил-2-аминопропандиола-1,3 | |
| CN119798107A (zh) | 一种dl-泛醇的制备方法 | |
| JPS63139181A (ja) | ２−（１０，１１−ジヒドロ−１０−オキソジベンゾ〔ｂ，ｆ〕チエピン−２−イル）プロピオン酸の結晶化方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131024 |